Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, Arizona.
Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan.
HLA. 2019 Jun;93(6):436-444. doi: 10.1111/tan.13515. Epub 2019 Apr 4.
The lymphocyte crossmatch is currently the only cell-based compatibility assay performed by histocompatibility laboratories for transplant purposes. While in many transplant programs the complement-dependent cytotoxicity crossmatch (CDCXM) remains in use, when available, the flow cytometry crossmatch (FCXM) is the method of choice because of its superior sensitivity and specificity. Unfortunately, the maintenance and cost of a flow cytometer is a considerable limitation for small histocompatibility laboratories. Therefore, in this study, we evaluated the use of the Cellometer Vision CBA image cytometer (Nexcelom Bioscience LLC, Lawrence, Massachusetts) as an alternative instrument to perform the crossmatch assay. The 3-color FCXM protocol was modified into two separate 2-color panel image cytometry crossmatches (IXMs), one for T cells and one for B cells. After initial serum and cell incubation, a cocktail consisting of PE/Cy5-conjugated anti-human CD3 or CD19 and PE-conjugated anti-human IgG F(ab') was added to the T cell and B cell panels, respectively. The final cell preparation was added to a separate counting chamber. Images were captured using the Cellometer Vision CBA, an image cytometer designed for cell counting, size analysis and fluorescence intensity measurement. Thirty-nine IXMs were performed and compared with the FCXM. We obtained a concordance sensitivity of 94.1% and 100% and specificity of 100% and 88.9% for T cells and B cells, respectively. The linearity of the system was verified using dilutions of a sample containing known donor-specific anti-HLA antibodies (DSA) against the target cells. This feasibility study demonstrates that the FCXM test could be easily adapted to the Cellometer Vision CBA image cytometer without compromising specificity and sensitivity. The low instrumentation cost, minimal maintenance, and simple operation allow for efficient implementation or transition from the FCXM to the IXM method.
淋巴细胞交叉配型目前是组织相容性实验室为移植目的进行的唯一基于细胞的相容性检测。虽然在许多移植项目中仍然使用补体依赖性细胞毒性交叉配型(CDCXM),但在有条件的情况下,流式细胞交叉配型(FCXM)因其更高的灵敏度和特异性而成为首选方法。不幸的是,流式细胞仪的维护和成本对于小型组织相容性实验室来说是一个相当大的限制。因此,在这项研究中,我们评估了使用 Cellometer Vision CBA 图像细胞仪(Nexcelom Bioscience LLC,马萨诸塞州劳伦斯)作为替代仪器来进行交叉配型检测的方法。将 3 色 FCXM 方案修改为两个单独的 2 色面板流式细胞术交叉配型(IXM),一个用于 T 细胞,一个用于 B 细胞。初始孵育血清和细胞后,将包含 PE/Cy5 标记的抗人 CD3 或 CD19 和 PE 标记的抗人 IgG F(ab')的鸡尾酒分别添加到 T 细胞和 B 细胞面板中。最后将细胞制备物添加到单独的计数室中。使用 Cellometer Vision CBA 捕获图像,该仪器是一种专为细胞计数、大小分析和荧光强度测量而设计的图像细胞仪。进行了 39 次 IXM,并与 FCXM 进行了比较。我们分别获得了 T 细胞和 B 细胞 94.1%和 100%的一致性灵敏度和 100%和 88.9%的特异性。通过使用含有针对靶细胞的已知供体特异性 HLA 抗体(DSA)的样本稀释液验证了系统的线性。这项可行性研究表明,FCXM 测试可以很容易地适应 Cellometer Vision CBA 图像细胞仪,而不会影响特异性和灵敏度。仪器成本低、维护要求低、操作简单,可以高效地实施或从 FCXM 方法过渡到 IXM 方法。